News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Paul Musey, MD, MSC

Peer-supported online therapy improves anxiety after emergency visits for low-risk chest pain

Randomized trial finds peer-supported online therapy improved anxiety after discharge for low-risk chest pain, with the largest difference among

Group photo showing all Regenstrief-affiliated participants in the 2026 AMIA Annual Symposium in Dallas, TX

Regenstrief highlighted AI and learning health systems research at AMIA 2026

Regenstrief Institute research scientists, fellows and affiliates shared work on artificial intelligence, health information exchange and public health informatics

photo of Dr. Josh Vest with New England Journal of Medicine logo

NEJM Perspective calls for screening tailored to older adults’ social needs

Regenstrief Institute and Weill Cornell Medicine researchers outline how health systems can identify unmet needs more accurately and connect

infographic showing findings of study

Examining how insurance coverage shapes access to kidney transplantation

Regenstrief researchers contribute to a national study highlighting differences between Medicare Advantage and traditional Medicare  For people with kidney